Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06991894 · ClinicalTrials.gov registry record
Real-world Outcomes of Aplastic Anemia Patients Treated With Eltrombopag: A Medical Claims Database Study
A clinical trial of Anemia, Aplastic, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 2,517
- Enrollment target
- 1
- Study location
NCT06991894 is a study of Anemia, Aplastic that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 2,517 participants, above the 38-participant average among 5 other Anemia, Aplastic trials with a reported enrollment target (6524% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06991894, a study of Anemia, Aplastic, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 2,517 participants
- Enrollment target
- 1
- Study location
Study Summary
The main goal of this study was to investigate the effectiveness and safety of eltrombopag (ETB) when compared to other treatments in Japanese aplastic anemia (AA) patients using data from the Medical Data Vision (MDV) hospital-based database.
Conditions Studied
Study Locations (1)
New Jersey
- Novartis - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,517 participants |
| Start Date | 2021-07-14 |
| Est. Completion | 2024-05-17 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06991894
The ClinicalTrials.gov registry entry for NCT06991894 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,517 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 38-participant average among 5 other Anemia, Aplastic trials with a reported enrollment target (6524% higher). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Anemia, Aplastic appearing as the primary indexed condition, and to 0 interventions.
NCT06991894 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT06991894 about?
NCT06991894 is a clinical study titled "Real-world Outcomes of Aplastic Anemia Patients Treated With Eltrombopag: A Medical Claims Database Study". The main goal of this study was to investigate the effectiveness and safety of eltrombopag (ETB) when compared to other treatments in Japanese aplastic anemia (AA) patients using data from the Medical Data Vision (MDV) hospital-based database.
What is the current status of trial NCT06991894?
This trial is currently completed. The enrollment target is 2,517 participants. The study started on 2021-07-14. Estimated completion is 2024-05-17.
What conditions does trial NCT06991894 study?
This clinical trial studies the following conditions: Anemia, Aplastic.
Who is sponsoring clinical trial NCT06991894?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06991894 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anemia, Aplastic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 1
-
Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States
COMPLETED · Phase 2
-
Partially Matched Stem Cell Transplantation for Patients With Refractory Severe Aplastic Anemia or Refractory Cytopenias
COMPLETED · NA
-
Unrelated Umbilical Cord Blood Transplantation Augmented With ALDHbr Umbilical Cord Blood Cells
COMPLETED · Phase 1
-
Rituximab to Treat Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.